Effects of etanercept injection: A Synthesis of Findings from 11 Studies

  1. Home
  2. Effects of etanercept injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of etanercept injection: A Synthesis of Findings from 11 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of etanercept injection: A Synthesis of Findings from 11 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Etanercept has been found to be effective in treating various autoimmune diseases such as hidradenitis suppurativa ( 7 ), plaque psoriasis ( 6 ), psoriatic arthritis ( 4 ), and rheumatoid arthritis ( 8 ). Etanercept was effective in treating hidradenitis suppurativa by improving skin manifestations. In psoriatic arthritis, etanercept was shown to reduce joint inflammation. Etanercept demonstrated efficacy in patients with rheumatoid arthritis who did not respond to combination therapies with disease-modifying antirheumatic drugs (DMARDs). Furthermore, etanercept may be an effective treatment option for psoriasis patients who have not responded to adalimumab ( 6 ). However, etanercept should be used with caution as it may induce severe generalized pustular psoriasis (GPP) in patients with psoriasis ( 5 ). Etanercept injection can cause injection site reactions (), which are characterized by a cell-mediated T(H)1 reaction with CD8+ T cells predominantly infiltrating the dermis ( 10 ). Etanercept liquid formulation is bioequivalent to the reconstituted lyophilized formulation ( 9 ). Etanercept can potentially prevent the deterioration of the Achilles tendon morphology induced by stress shielding ( 2 ). Additionally, etanercept subcutaneous injections can induce panniculitis with lipid crystallization within adipocytes ( 3 ).

Benefits and Risks

Benefit Summary

Etanercept holds potential benefits in treating autoimmune diseases such as hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. It may also be effective for psoriasis patients who have not responded to adalimumab. Both liquid and reconstituted lyophilized formulations of etanercept exhibit similar bioavailability. Etanercept can potentially protect against stress-shielded Achilles tendon deterioration.

Risk Summary

Etanercept can cause severe generalized pustular psoriasis (GPP) in psoriasis patients. Additionally, it may lead to injection site reactions and panniculitis with lipid crystallization. Consulting a doctor is essential to understand and manage these risks.

Comparison between Studies

Commonalities

Many studies evaluate the safety and efficacy of etanercept. They investigate its effects on different autoimmune diseases. Some studies also explore various dosage and administration methods of etanercept.

Differences

Studies differ in the specific diseases targeted and the assessment criteria used. For example, some studies evaluate skin manifestations in hidradenitis suppurativa, while others assess joint inflammation in rheumatoid arthritis. The dosage and administration methods of etanercept can also vary across studies.

Consistency and Discrepancies in Findings

Multiple studies demonstrate the effectiveness of etanercept in treating a range of autoimmune diseases. However, it is crucial to be cautious as etanercept can induce severe generalized pustular psoriasis. Additionally, risks such as injection site reactions and panniculitis with lipid crystallization exist. Understanding these risks and consulting a doctor is essential when considering etanercept treatment.

Considerations for Real-World Application

While etanercept is a potentially effective treatment for autoimmune diseases, it is not universally effective for all patients. Given its associated risks, consulting a doctor and receiving appropriate treatment are vital. If considering etanercept, discuss the risks and benefits thoroughly with your doctor to fully understand the implications.

Limitations of Current Research

Further research is needed to fully understand the long-term effects and safety of etanercept. Additionally, studies are required to determine which types of autoimmune diseases are most responsive to etanercept and which patients are best suited for this treatment.

Future Research Directions

Future research should focus on evaluating the long-term efficacy and safety of etanercept. Investigating the effects of etanercept on various autoimmune diseases in more detail is also crucial. Research should address which types of autoimmune diseases are most responsive to etanercept and identify the optimal patient profiles for etanercept treatment.

Conclusion

Etanercept holds potential as a treatment for autoimmune diseases like hidradenitis suppurativa, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. However, it is essential to be aware of potential risks, including severe generalized pustular psoriasis, injection site reactions, and panniculitis with lipid crystallization. Consult with your doctor to understand these risks and make informed decisions regarding etanercept treatment. Before starting etanercept, thoroughly discuss the potential risks and benefits with your physician.

Literature analysis of 11 papers
Positive Content
7
Neutral Content
0
Negative Content
4
Article Type
4
0
0
0
11
1.

Eszopiclone versus zopiclone in the treatment of insomnia.

Author: PintoLuciano Ribeiro, BittencourtLia Rita Azeredo, TreptowErika Cristine, BragaLuciano Rotella, TufikSergio

Sleep improvement
Insomnia

Eszopiclone demonstrated efficacy comparable to that of zopiclone in the treatment of insomnia, increasing total sleep time as well as sleep efficiency according to polysomnography. The primary efficacy analysis demonstrated the non-inferiority of eszopiclone over zopiclone. Analysis of objective parameters assessed by polysomnography showed that eszopiclone increased total sleep time and also improved sleep efficiency.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Panniculitis with crystals induced by etanercept subcutaneous injection.

Author: Llamas-VelascoMar, RequenaLuis

Panniculitis

This study reports a patient who developed a panniculitis with lipid crystallization at the site of etanercept injection.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

4.

Synovial biomarkers in psoriatic arthritis.

Author: FioccoUgo, OlivieroFrancesca, SfrisoPaolo, CalabreseFiorella, LunardiFrancesca, ScaglioriElena, RubaltelliLeopoldo, StramareRoberto, Di MaggioAntonio, NardacchioneRoberto, CozziLuisella, MolenaBeatrice, FelicettiMara, GazzolaKatia, Lo NigroAlessandro, AccordiBenedetta, Roux-LombardPascale, DayerJean-Michel, PunziLeonardo

PsA biomarker

This study analyzed a panel of synovial fluid and synovial tissue biomarkers in patients with resistant peripheral psoriatic arthritis (PsA) to identify potential biomarkers for PsA. The results may help to develop better diagnostic and treatment strategies for PsA.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Successful treatment of von Zumbusch generalized pustular psoriasis with cyclosporine after eruption post etanercept injection.

Author: EphremGeorges, JourGeorge, SmithBarry L

Generalized pustular psoriasis

A 22-year-old woman developed a severe eruption of generalized pustular psoriasis 48 hours after receiving an etanercept injection.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

6.

An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab.

Author: VenderRonald

Psoriasis treatment
Limited data
Treatment failures

There are five biologic agents approved for the treatment of psoriasis, but switching to a different biologic after losing response to the first is a common practice.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Treatment of hidradenitis suppurativa with etanercept injection.

Author: AdamsDavid R, YankuraJessica A, FogelbergAnneli C, AndersonBryan E

Etanercept, 50 mg, administered subcutaneously twice weekly did not demonstrate significant efficacy in improving the cutaneous manifestations of hidradenitis suppurative (HS).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Improvement of active rheumatoid arthritis after etanercept injection: a single-center experience.

Author: SuKuei-Ying, LeeHui-Ting, ChouChung-Tei, TsaiShih-Tzu, ChenWei-Sheng, TsaiChang-Youh

Aching symptom improvement
Rheumatoid arthritis treatment
Infections
Injection site reaction

Combination therapy with etanercept and DMARDs is effective in improving rheumatoid arthritis symptoms and is generally safe. Significant improvement was observed as early as 3 months after treatment initiation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections.

Author: SullivanJohn T, NiLiyun, SheeloClaudia, SalfiMargaret, PelosoPaul M

This study compared the pharmacokinetics of liquid and reconstituted lyophilized etanercept. The liquid formulation was found to be bioequivalent to the reconstituted lyophilized formulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

10.

Eosinophilic cellulitislike reaction to subcutaneous etanercept injection.

Author: WinfieldHarry, LainEdward, HornThomas, HoskynJerri

Injection site reaction

Eosinophilic cellulitis as a response to etanercept has not been reported to date.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

11.

Bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections.

Author: SullivanJohn T, NiLiyun, SheeloClaudia, SalfiMargaret, PelosoPaul M

This study compared the pharmacokinetics of liquid and reconstituted lyophilized etanercept. The liquid formulation was found to be bioequivalent to the reconstituted lyophilized formulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.